Genomica, a Spanish company specializing in molecular diagnosis, has been exploded by the coronavirus epidemic at its best. Two years ago he opened an office in Wuhan, the city that today is the epicenter of the latest global health threat. He established warehouses in the city and began to create networks of collaboration with local companies. Now this subsidiary of PharmaMar is the best placed company to supply rapid diagnostic kits for the new pathogen and competes with other international companies.
If the deadlines are met as planned, Genomica hopes to obtain an accelerated approval from the Agency for Medicines and Health Products to present the new tests in the second week of March. ...
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.
